Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Hypertension
Interventions: losartan potassium / hydrochlorothiazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Lamotrigine, Lamictal®; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 20 Years to 44 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Quadrangle Drive, North Carolina

Conditions: Diet Habit
Interventions: Healthy Default Kids' Beverage Policy; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 3,480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Research Triangle Park, North Carolina • Philadelphia, Pennsylvania

Conditions: Mental Disorders
Interventions: Lamotrigine IR tablets, Lamotrigine ODT tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Smoking
Interventions: Informing surgical patients about CO monitoring, a brief intervention recommending preoperative abstinence from smoking; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Infants of Diabetic Mothers
Interventions: N/A - No intervention; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: Up to 45 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: Mycophenolate Mofetil, CellCept®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bulimia Nervosa
Interventions: Fasting state, Fed state, Magnetic Resonance Imaging; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus, Healthy Subjects
Interventions: sotagliflozin (SAR439954); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Broadway, Florida

Conditions: Healthy
Interventions: Seltorexant 40 mg, Seltorexant 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer Study
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hyperglycemia, Diabetes, and Obesity
Interventions: Resistant starch; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions: Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Loxapine Succinate Capsules 25 mg, Loxitane® Capsules 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Prostate Neoplasms
Interventions: Stage 1 Group 1: abiraterone acetate, Stage 1 Group 2: abiraterone acetate, Stage 2: abiraterone acetate, Stage 3: abiraterone acetate, Stage 3: glucocorticoid, Stage 4: abiraterone acetate, Stage 4: glucocorticoid; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Improving Cardiometabolic Outcomes in Older Adults
Interventions: Melatonin 1 mg, Placebos, Meal timing, Non-Meal timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions: Fibroscan; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Type 2 Diabetes
Interventions: Intermittent energy restriction (IER), Time Restricted Eating (TRE); Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Influenza
Interventions: Placebo for VNT-101, VNT-101; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Telephonic intervention to prevent Diabetes Mellitus, Type 2; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 74 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: Leflunomide 20 mg Tablets, ARAVA™ 20 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Obesity, Colorectal Cancer, Microbial Colonization, Time Restricted Feeding, Stress, Psychological
Interventions: TRE, MBSR; Behavioral
Lead sponsor: Lisa Tussing-Humphreys; Other
Eligibility: 18 Years to 39 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

Evaluating a Healthy Restaurant Kids Meals Policy

Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers

Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation

Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

Changes in Inhibition and Valuation After Eating

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

Effects of Resistant Starch in a Baked Snack Bar on a Post-prandial Glycemic and Insulinemic Response

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

Aging Program Project Grant 6

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

Call-2-Health: Preventing Type II Diabetes

Leflunomide 20 mg Tablets Under Fasting Conditions

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer